Mature results of a prospective randomized trial comparing a three-weekly with an accelerated weekly schedule of cisplatin in advanced ovarian carcinoma.

In a retrospective analysis of a series of clinical trials by Levin and Hryniuk in 1987, the average relative dose intensity of first-line chemotherapy for advanced ovarian cancer correlated significantly with clinical response and survival, and cisplatin was the only drug for which the outcome correlated with the individual drug relative dose intensity. There was a need to test whether and to what extent this evidence would be confirmed in a prospective evaluation. In this study 101 patients with advanced ovarian carcinoma were randomized to receive the same total dose of cisplatin but at the conventional 3-weekly schedule (CTWS) (100 mg/m2 every 3 weeks for six cycles) (51 patients) or at an experimental accelerated weekly schedule (AWS) (100 mg/m2 every week for two triplets of three cycles separated by a 5-week interval) (50 patients). To benefit from a multidrug regimen at the same extent, patients in both arms sequentially received four cycles of doxorubicin and cyclophosphamide. The median follow-up period of this study is 9.7 years. In 42 and 40 patients of the two arms having evaluable response, the clinical complete response rates to cisplatin were 14% and 22% and the complete plus partial response rates were 48% and 55% in the CTWS and in the AWS arm, respectively. These differences were not statistically significant. However, the survival curves were similar during the first 2 years but clearly diverged thereafter in favor of the AWS arm (p = 0.07). At 5 years, 12% and 30% of the patients were still alive in the CTWS and in the AWS arm, respectively. Hematologic toxicity was not relevant in either arm of the study. Nonhematologic toxicity, especially ototoxicity, was substantial and significantly higher in the AWS arm. Although statistically nonsignificant, this AWS regimen of cisplatin is associated with long-term better survival compared to the CTWS regimen in advanced ovarian carcinoma. This accelerated approach administering cisplatin should be further investigated, especially in patients with low residual disease after primary surgery.

[1]  W. Hryniuk,et al.  The calculation of received dose intensity. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[3]  W. Hryniuk,et al.  Dose intensity analysis of chemotherapy regimens in ovarian carcinoma. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  A. Miller,et al.  Reporting results of cancer treatment , 1981, Cancer.

[5]  Marc Buyse,et al.  Cyclophosphamide Plus Cisplatin Versus Cyclophosphomide, Doxorubicin, and Cisplatin Chemotherapy of Ovarian-carcinoma - a Metaanalysis , 1991 .

[6]  A. Gadducci,et al.  High-dose versus low-dose cisplatin in combination with cyclophosphamide and epidoxorubicin in suboptimal ovarian cancer: a randomized study of the Gruppo Oncologico Nord-Ovest. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  M. Gore,et al.  Randomized trial of dose-intensity with single-agent carboplatin in patients with epithelial ovarian cancer. London Gynaecological Oncology Group. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  D. Cruickshank,et al.  Mature results of a randomized trial of two doses of cisplatin for the treatment of ovarian cancer. Scottish Gynecology Cancer Trials Group. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  J. Berek,et al.  Assessment of dose-intensive therapy in suboptimally debulked ovarian cancer: a Gynecologic Oncology Group study. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  C. W. Wilson,et al.  Letter: Fenfluramine and dreaming. , 1974, Lancet.

[11]  M. Pike,et al.  Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. , 1977, British Journal of Cancer.

[12]  D. Alberts,et al.  Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. , 1996, The New England journal of medicine.

[13]  J. Neijt,et al.  RANDOMISED TRIAL COMPARING TWO COMBINATION CHEMOTHERAPY REGIMENS (HEXA-CAF VS CHAP-5) IN ADVANCED OVARIAN CARCINOMA , 1984, The Lancet.

[14]  E. Partridge,et al.  Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer , 1996, New England Journal of Medicine.

[15]  H. Ngan,et al.  A randomized study of high-dose versus low-dose cis-platinum combined with cyclophosphamide in the treatment of advanced ovarian cancer. Hong Kong Ovarian Carcinoma Study Group. , 1989, Chemotherapy.

[16]  D. Alberts,et al.  Chemotherapy in advanced ovarian cancer: an overview of randomised clinical trials. Advanced Ovarian Cancer Trialists Group. , 1991, BMJ.

[17]  Randomised study of two doses of cisplatin with cyclophosphamide in epithelial ovarian cancer , 1992, The Lancet.

[18]  D. Fennelly Dose intensity in advanced ovarian cancer: have we answered the question? , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

[19]  J. Glick,et al.  Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  M. Gore,et al.  Impact of doxorubicin on survival in advanced ovarian cancer. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.